SEARCH

SEARCH BY CITATION

References

  • 1
    Hardisty RM, Macpherson JC. A one-stage factor VIII (antihemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrag 1962; 7: 21529.
  • 2
    Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessment of factor VIII activity. Haemophilia 1998; 4: 64650.
  • 3
    Barrowcliffe TW. Factor VIII and factor IX sub-committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70: 8767.
  • 4
    Dawson NJ, Kemball-Cook G, Barrowcliffe TW. Assay discrepancies with highly purified Factor VIII concentrates. Haemostasis 1989; 19: 1317.
  • 5
    Ingram GI. Blood-coagulation factor 8: genetics, physiological control, and bioassay. Adv Clin Chem 1965; 8: 189236.
  • 6
    Kirkwood TB, Rizza CR, Snape TJ, Rhymes IL. Identification of sources of inter-laboratory variation in factor VIII assay. Br J Haematol 1977; 37: 55968.
  • 7
    Barrowcliffe TW, Kirkwood TB. An international collaborative assay of factor VIII clotting activity. Thromb Haemost 1978; 40: 26071.
  • 8
    Kirkwood TB. Problems in the standardization of Factor VIII assays. Scand J Haematol Suppl 1980; 37: 1105.
  • 9
    Heldebrant C, Kleszynski R, Short M, Aronson D, Brown L, Jacoby G, Lee M, Thomas D, Barrowcliffe T, Howell I, Johnson RC. Assay of AHF concentrates and standards: failure to eliminate variability with a monographed assay. Thromb Res 1983; 30: 33746.
  • 10
    Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2000; 84: 9428.
  • 11
    Mazurier C, Parquet-Gernez A, Goudemand M. Validation of a procedure for potency assessing of a high purity factor VIII concentrate – comparison of different factor VIII coagulant assays and effect of prediluent. Thromb Haemost 1990; 64: 2515.
  • 12
    Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 24756.
  • 13
    Raut S, Sands D, Heath AB, Barrowcliffe TW. Variability in factor VIII concentrate measurement: results from SSC field collaborative studies. J Thromb Haemost 2003; 1: 192734.
  • 14
    Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998; 4: 63440.
  • 15
    Barrowcliffe TW, Mertens K, Preston FE, Ingerslev J. Laboratory aspects of haemophilia therapy. Haemophilia 2002; 8: 2449.
  • 16
    Barrowcliffe TW. Standardization of FVIII & FIX assays. Haemophilia 2003; 9: 397402.
  • 17
    Lee ML, Maglalang EA, Kingdon HS. An effect of predilution on potency assays of factor VIII concentrates. Thromb Res 1983; 30: 5119.
  • 18
    Preston FE, Kitchen S. Quality control and factor VIII assays. Haemophilia 1998; 4: 6513.
  • 19
    Preston FE, Kitchen S, Jennings I, Woods TAL, Makris M. SSC/ISTH classification of haemophilia A: can hemophilia center laboratories achieve the new criteria? J Thromb Haemost 2004; 2: 2714.
  • 20
    Lollar P. The factor VIII assay problem: neither rhyme nor reason. J Thromb Haemost 2003; 1: 22759.
  • 21
    Frandsen H, Stender S, Sceibel E. An effect of predilution on VIII:C determination by one-stage assay. Thromb Res 1987; 48: 195203.
  • 22
    Morfini M, Cinotti S, Bellatreccia A, Paladino E, Gringeri A, Mannucci PM. A multicentre pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost 2003; 1: 22839.